Diurnal variation in P-glycoprotein-mediated transport and cerebrospinal fluid turnover in the brain

AAPS Journal

Volumn 16, Issue 5, 2014, Pages 1029-1037

  Kervezee, Laura ^a,b   Hartman, Robin ^a   Van Den Berg, Dirk Jan ^a   Shimizu, Shinji ^a   Emoto Yamamoto, Yumi ^a   Meijer, Johanna H ^b   De Lange, Elizabeth C M ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

blood brain barrier; chronobiology; intrabrain distribution; microdialysis; PBPK modeling

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN; QUINIDINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BRAIN HOMOGENATE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID FLOW; CIRCADIAN RHYTHM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG TRANSPORT; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR FLUID; IN VIVO STUDY; MALE; MICRODIALYSIS; NONHUMAN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; RAT; ANIMAL; BIOLOGICAL MODEL; BLOOD; BRAIN; CEREBROSPINAL FLUID; COMPARATIVE STUDY; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; TIME; TRANSPORT AT THE CELLULAR LEVEL; WISTAR RAT;

ANIMALS; BIOLOGICAL TRANSPORT; BRAIN; CIRCADIAN RHYTHM; DRUG ADMINISTRATION SCHEDULE; INJECTIONS, INTRAVENOUS; MALE; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; QUINIDINE; RATS, WISTAR; TIME FACTORS;

EID: 84908356769     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-014-9625-4     Document Type: Article

References (32)

1. Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37:13-25.
2. Ohtsuki S, Terasaki T. Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm Res. 2007;24:1745-58. (Pubitemid 47206624)
3. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994;77:491-502. (Pubitemid 24153990)
4. Bendayan R, Ronaldson PT, Gingras D, Bendayan M. In situ localization of P-glycoprotein (ABCB1) in human and rat brain. J Histochem Cytochem. 2006;54:1159-67. (Pubitemid 44434719)
5. Potschka H. Targeting regulation of ABC efflux transporters in brain diseases: a novel therapeutic approach. Pharmacol Ther. 2010;125:118-27.
6. Dallmann R, Brown SA, Gachon F. Chronopharmacology: new insights and therapeutic implications. Annu Rev Pharmacol Toxicol Ann Rev. 2014;54:339-61.
7. Watanabe J, Suzuki Y, Fukui N, Ono S, Sugai T, Tsuneyama N, et al. Increased risk of antipsychotic-related QT prolongation during nighttime: a 24-hour holter electrocardiogram recording study. J Clin Psychopharmacol. 2012;32:18-22.
8. Hermida RC, Ayala DE, Fernández JR, Calvo C. Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. Hypertension. 2008;51:69-76. (Pubitemid 350307106)
9. Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E, et al. Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Ann Rheum Dis. 2010;69:1275-80.
10. Ando H, Yanagihara H, Sugimoto K, Hayashi Y, Tsuruoka S, Takamura T, et al. Daily rhythms of P-glycoprotein expression in mice. Chronobiol Int. 2005;22:655-65. (Pubitemid 41361729)
11. Murakami Y, Higashi Y, Matsunaga N, Koyanagi S, Ohdo S. Circadian clock-controlled intestinal expression of the multidrug-resistance gene mdr1a in mice. Gastroenterology. 2008;135:1636-44.e3.
12. Hayashi Y, Ushijima K, Ando H, Yanagihara H, Ishikawa E, Tsuruoka S-I, et al. Influence of a time-restricted feeding schedule on the daily rhythm of abcb1a gene expression and its function in rat intestine. J Pharmacol Exp Ther. 2010;335:418-23.
13. Okyar A, Dressler C, Hanafy A, Baktir G, Lemmer B, Spahn-Langguth H. Circadian variations in exsorptive transport: in situ intestinal perfusion data and in vivo relevance. Chronobiol Int. 2012;29:443-53.
14. Ballesta A, Dulong S, Abbara C, Cohen B, Okyar A, Clairambault J, et al. A combined experimental and mathematical approach for molecular-based optimization of irinotecan circadian delivery. PLoS Comput Biol. 2011;7:e1002143.
15. Stearns AT, Balakrishnan A, Rhoads DB, Ashley SW, Tavakkolizadeh A. Diurnal rhythmicity in the transcription of jejunal drug transporters. J Pharmacol Sci. 2008;108:144-8.
16. De Lange ECM. The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects. Fluids Barriers CNS. 2013;10:12.
17. Westerhout J, Smeets J, Danhof M, de Lange ECM. The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid. J Pharmacokinet Pharmacodyn. 2013;40:327-42.
18. Moghaddam B, Bunney BS. Ionic composition of microdialysis perfusing solution alters the pharmacological responsiveness and basal outflow of striatal dopamine. J Neurochem. 1989;53:652-4. (Pubitemid 19186107)
19. Syvänen S, Schenke M, van den Berg D-J, Voskuyl RA, de Lange EC. Alteration in P-glycoprotein functionality affects intrabrain distribution of quinidine more than brain entry-a study in rats subjected to status epilepticus by kainate. AAPS J. 2012;14:87-96.
20. Meijer JH, Colwell CS, Rohling JHT, Houben T, Michel S. Dynamic neuronal network organization of the circadian clock and possible deterioration in disease. Prog Brain Res. 2012;199:143-62.
21. Mohawk JA, Green CB, Takahashi JS. Central and peripheral circadian clocks in mammals. Annu Rev Neurosci Annu Rev. 2012;35:445-62.
22. Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, et al. Sleep drives metabolite clearance from the adult brain. Science. 2013;342:373-7.
23. Scism JL, Powers KM, Artru AA, Lewis L, Shen DD. Probenecid-inhibitable efflux transport of valproic acid in the brain parenchymal cells of rabbits: a microdialysis study. Brain Res. 2000;884:77-86.
24. Baltes S, Fedrowitz M, Tortós CL, Potschka H, Löscher W. Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J Pharmacol Exp Ther. 2007;320:331-43. (Pubitemid 46025748)
25. Golden PL, Pardridge WM. P-glycoprotein on astrocyte foot processes of unfixed isolated human brain capillaries. Brain Res. 1999;819:143-6. (Pubitemid 29225465)
26. Shimizu F, Sano Y, Maeda T, Abe M-A, Nakayama H, Takahashi R-I, et al. Peripheral nerve pericytes originating from the blood-nerve barrier expresses tight junctional molecules and transporters as barrier-forming cells. J Cell Physiol. 2008;217:388-99.
27. Volk H, Burkhardt K, Potschka H, Chen J, Becker A, Löscher W. Neuronal expression of the drug efflux transporter P-glycoprotein in the rat hippocampus after limbic seizures. Neuroscience. 2004;123:751-9. (Pubitemid 38045412)
28. Lazarowski A, Caltana L, Merelli A, Rubio MD, Ramos AJ, Brusco A. Neuronal mdr-1 gene expression after experimental focal hypoxia: a new obstacle for neuroprotection? J Neurol Sci. 2007;258:84-92. (Pubitemid 46876736)
29. Kreisl WC, Liow J-S, Kimura N, Seneca N, Zoghbi SS, Morse CL, et al. P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide. J Nucl Med. 2010;51:559-66.
30. Wagner CC, Bauer M, Karch R, Feurstein T, Kopp S, Chiba P, et al. A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET. J Nucl Med. 2009;50:1954-61.
31. Bauer M, Zeitlinger M, Todorut D, Böhmdorfer M, Müller M, Langer O, et al. Pharmacokinetics of single ascending doses of the P-glycoprotein inhibitor tariquidar in healthy subjects. Pharmacology. 2013;91:12-9.
32. Kalvass JC, Polli JW, Bourdet DL, Feng B, Huang S-M, Liu X, et al. Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position. Clin Pharmacol Ther. 2013;94:80-94.